Filter posts

Value Drivers Under the Influence – How Licensing and Key Events Affect Valuation

The Tuesday plenary luncheon at the 2012 BIO CEO & Investor Conference featured a panel …

Picks and Pans – The Buy-Side View for 2012

What’s the forecast for biotech in 2012? Do investors think it is a good time …

Fireside Chat with Moncef Slaoui, GlaxoSmithKline

Moncel Slaoui, chairman of research and development (R&D) at GlaxoSmithKline (GSK), opened the 2012 BIO …

Managing in a Cost-Constrained Environment

By Jill E. Sackman, D.V.M., Ph.D., Senior Consultant, and Matt Levy, J.D., Business Analyst, at …

2012 BIO International Convention to Highlight Breakthroughs

2012 BIO International Convention to Highlight Breakthroughs in Healing, Fueling, and Feeding the World The …

Sizing up the NBI in 2011

How did the Nasdaq Biotechnology Index (NBI) perform in 2011 relative to other sectors? Second …

Biomedical Innovation: How the U.S. Can Stay Number One

By Ross DeVol, chief research officer of the Milken Institute “The first step in winning …

Just how big is $11 Billion? GILD Acquires VRUS

Seeing the markets open down 2% or more on a Monday morning feels like “business …

Reverse Mergers: A Company is Ready to Go Public, or it’s Not

The latest IPO window has stalled. There have been five IPO withdrawals since June and …

Perspective on Market Valuation for Biotech Drug Developers

Of the 300 publicly traded U.S. biotechs, 219 (73%) are developing drugs. The other 27% …